Company Description
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics.
The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, urinary tract infection, sepsis, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment of chronic organ disease, including chronic kidney disease.
It is also developing REVTx-99b, a treatment for food allergies; REVTx-99a, an anti-viral nasal drop solution for the potential prevention or treatment of respiratory viral infection; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, influenza A, influenza B, parainfluenza, or respiratory syncytial virus.
The company was founded in 2020 and is based in San Diego, California.
| Country | United States |
| Founded | 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | James M. Rolke |
Contact Details
Address: 4660 Lajolla Village Drive, Suite 100 San Diego, California 92122 United States | |
| Phone | 650-800-3717 |
| Website | revbiosciences.com |
Stock Details
| Ticker Symbol | REVB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001810560 |
| CUSIP Number | 76135L101 |
| ISIN Number | US76135L5075 |
| Employer ID | 84-3898466 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| James M. Rolke | Chief Executive Officer and Director |
| Chester Stanley Zygmont III | Chief Financial Officer and Corporate Secretary |
| Sandra Vedrick | Vice President of Human Resources and Investor Relations |
| Carol Odle | Senior Director of Clinical Projects |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 5, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 22, 2024 | 8-K | Current Report |
| Mar 22, 2024 | 10-K | Annual Report |
| Mar 12, 2024 | 8-K | Current Report |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2024 | SCHEDULE 13G/A | Filing |
| Feb 8, 2024 | 8-K | Current Report |
| Feb 2, 2024 | 424B3 | Prospectus |
| Jan 31, 2024 | EFFECT | Notice of Effectiveness |